FGFR2 and cholangiocarcinoma: Promising therapeutic molecular targets for CCA have been identified and include isocitrate dehydrogenases 1 and 2 (IDH1 and 2) and products of fusions of the fibroblast growth factor receptor 2 (FGFR2) gene [17].